Cape Town-based research technology company Yazi has raised its first institutional funding round from 3 Capital Ventures (3CV), the early-stage venture firm that originated inside Allan Gray, as enterprises and development organisations increasingly adopt WhatsApp as a channel for customer and population research. Founded in 2022 by Timothy Treagus (CEO) and Mzwandile Sotsaka (CTO), Yazi […]
Private equity firm EQT AB is reportedly exploring a sale of SUSE that could value the open-source Linux pioneer at up to $6 billion, roughly doubling the valuation since EQT took the company private in 2023. Reuters reports: EQT “has hired investment bank Arma Partners to sound out a group of private equity investors for a possible sale of the company, said the sources, who requested anonymity...
An anonymous reader quotes a report from Ars Technica: This week, tens of thousands of game developers and producers will once again gather in San Francisco, as they have since 1988, for the weeklong Game Developers Conference. But this year’s show will be missing many international developers who say they no longer feel comfortable traveling to the United States to attend, no matter how...
Google has injected Docs, Drive, Sheets, and Slides with its Gemini assistant, adding new features that can pull information from your emails and the web to help you draft content. I gave it a whirl.
At $599, the MacBook Neo is Apple’s first budget laptop. For the most part, Apple cut corners in the right places and made a MacBook its intended buyers will adore.
The iPhone 17e is here. Here are all the details on Apple’s smartphones to help you find the right model, whether that’s the ultralight iPhone Air or the orange iPhone 17 Pro.
UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds
Business live – latest updates
The pipeline of drugs to fight superbugs remains “worryingly thin” and has shrunk by 35% in the last five years, experts have warned, predicting the annual number of deaths linked to drug-resistant infections globally will double to 8 million by 2050.